Latest Metformin Stories
A large-scale study from Cardiff University reveals that people with Type 2 diabetes can live longer than those without the condition, thanks to a widely prescribed blood glucose control medication.
In Phase 3 studies, INVOKANA® plus metformin lowered blood sugar and reduced secondary endpoints of body weight and systolic blood pressure to a greater degree than metformin alone RARITAN,
Metformin and SGLT2 inhibitors together reduce the blood sugar levels considerably more effectively than either drug alone.
- Combination of linagliptin and metformin significantly reduced blood glucose levels compared with linagliptin alone RIDGEFIELD, Conn. and INDIANAPOLIS, Aug.
LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Labeling people with moderately high blood sugar as pre-diabetic is a drastically premature measure with no medical value and huge financial and social costs
--Microbiome Modulator NM504 Significantly Improved Blood Glucose Control and Other Metabolic Parameters in Patients with Prediabetes and Type 2 Diabetes-- CHICAGO and BROOMFIELD,
- Recent Publication Shows Metformin Improves Glycemic Control by Modulating the Gut Microbiome and Triggering Specific Cellular and Immune Mechanisms - BROOMFIELD, Colo., June
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA® (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo.
-- In a two-year study, empagliflozin as add-on to metformin demonstrated significantly greater decreases in A1C (blood glucose), body weight and blood pressure compared with glimepiride as add-on
- The act of sweetening by admixture of some saccharine substance.